Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 13, 2023 14:03 ET | Source: BioAegis Therapeutics

BioAegis Therapeutics Announces Two Studies Exploring the Role of ‘Inflammation Regulator’ Gelsolin in Type 2 Diabetes

Gelsolin decreased microparticle-driven inflammation and mitigated activation of the NLRP3 inflammasome in type 2 diabetes. Low levels of gelsolin identified in individuals with type 2 diabetes...
September 15, 2016 19:26 ET | Source: XOMA Ltd.

XOMA Provides Update from Ongoing Phase 2 XOMA 358 Clinical Studies

Results Demonstrate XOMA 358 Mechanism-of-Action in Rare Endocrine ConditionsCompany Plans to Advance XOMA 358 to Multi-dose Phase 2b Studies BERKELEY, Calif., Sept. 15, 2016 (GLOBE...
September 06, 2016 09:00 ET | Source: XOMA Ltd.

XOMA to Host XOMA 358 Clinical Update Webcast and Conference Call on September 15, 2016

BERKELEY, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it will host a webcast and...
April 17, 2013 11:39 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals Awarded Phase II Funding of NIH Fast -Track SBIR Grant to Advance Glucagon for the Artificial Pancreas

Austin, TX, April 17, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based, pharmaceutical company developing patient-friendly injectable treatments for diabetes and other...